A stability-indicating high performance liquid chromatography method to determine apocynin in nanoparticles

Juliana Kovalczuk de Oliveira\textsuperscript{a}, Débora Fernanda Veres Ronik\textsuperscript{a}, Jociani Ascarib, Rubiana Mara Mainardes\textsuperscript{a}, Najeh Maissar Khalil\textsuperscript{a,b}\textsuperscript{*}

\textsuperscript{a} Department of Pharmacy, Laboratory of Pharmaceutical Nanotechnology, Universidade Estadual do Centro-Oeste, Rua Simão Camargo Varela de Sá, 85040-080 Guarapuava, Brazil
\textsuperscript{b} Department of Biological Sciences, Universidade Tecnológica Federal do Paraná, Rua Cerejeiras S/N, 85892-000 Santa Helena, PR, Brazil

\textbf{A R T I C L E  I N F O}

Keywords:
Apocynin
Nanoparticles
Bovine serum albumin
HPLC

\textbf{A B S T R A C T}

In this study, we developed and validated a fast, specific, sensitive, precise and stability-indicating high performance liquid chromatography (HPLC) method to determine the drug apocynin in bovine serum albumin (BSA) nanoparticles. Chromatographic analyses were performed on an RP-C\textsubscript{18} column and using a photodiode array detector at a wavelength of 276 nm. Mobile phase consisted of a mixture of acetonitrile and 1\% acetic acid (60:40, v/v), and it was eluted isocratically at a flow rate of 0.8 mL/min. The retention time of apocynin chromatographic peak was 1.65 min. The method was linear, precise and accurate in the range of 5–100 \(\mu\)g/mL. The intra- and inter-day precisions presented relative standard deviation (RSD) values lower than 2\%. The method was robust regarding changes in mobile phase proportion, but not for flow rate. Limits of detection and quantitation were 78 ng/mL and 238 ng/mL, respectively. Apocynin was exposed to acid and alkali hydrolysis, oxidation and visible light. The drug suffered mild degradation under acid and oxidation conditions and great degradation under alkali conditions. Light exposure did not degrade the drug. The method was successfully applied to determine the encapsulation efficiency of apocynin in BSA nanoparticles.

1. Introduction

Apocynin (4-hidroxy-3-methoxyacetophenone) is a methoxy-catechol originally extracted from the roots of \textit{Picrorhiza kurroa Royle} (Scrophulariaceae) native to the Himalaya [1,2]. This drug presents potential anti-inflammatory and antioxidant properties [2,3] and also is widely described as a specific NADPH oxidase inhibitor [4–6]. The inhibition of NADPH oxidase represents a therapeutic target to prevent various diseases such as cancer [7–9], atherosclerosis [10], vascular and neurodegenerative diseases [11,12]. However, apocynin presents pharmacokinetics limitations such as low oral bioavailability and rapid elimination [13], and narrow dose-response relationship [14], thus limiting its clinical application.

Nanostructured systems have been widely used to improve physicochemical and biological properties of compounds. The in vivo efficacy of nanoparticles as drug carrier systems depends upon particle size, surface properties and release pattern of the drug loaded. The nanocapsulation of a drug is an interesting strategy to improve biopharmaceutical and pharmacokinetics properties of the drug, leading to an improvement of the biological effects [15–18].

Nanoparticles can be composed of natural or synthetic polymers [16,19–21]. Natural polymers commonly used originate from proteins such as albumin, collagen and gelatin or from polysaccharides such as alginate, chitosan, and dextran [22,23]. Bovine serum albumin (BSA) has been used for the preparation of nanostructured materials due to its high stability and antigenicity, allowing to obtain nanoparticles with low toxicity and immunogenicity [24–26].

There are a few works in the literature about apocynin determination and quantification by analytical methods. Wang et al. [27] evaluated the bioavailability of apocynin in plasma, liver and brain tissues using liquid chromatography–mass spectrometry (LC–MS). Trumbull et al. [28] determined accumulation of apocynin and diapocynin in the brain and spinal cord tissue by high performance liquid chromatography (HPLC) with selective ion monitoring by mass spectrometry. Wang et al. [13] reported an HPLC method with ultraviolet (UV) detection for the pharmacokinetics evaluation of apocynin. Recently, Chandasana et al. [29] developed a sensitive and selective method by liquid chromatography–tandem mass spectro-
2. Material and methods

2.1. Chemicals and reagents

Apocynin (Acetovanillone 98%) and bovine serum albumin (BSA) (≥98%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ethyl alcohol was obtained from FMAia (São Francisco, MG, Brazil). Glutaraldehyde (25%) and acetic acid were from Vetec (Rio de Janeiro, RJ, Brazil). HPLC-grade acetonitrile was from JTBaker (Philipsburg, NJ, USA). For all analyses, ultrapure water was obtained from Millipore Milli-Q Plus apparatus (Millipore, Rio de Janeiro, RJ, Brazil). All solvents and chemicals used were of analytical or HPLC grade.

2.2. Instruments and chromatographic conditions

The analytical method was developed and validated on a Waters 2695 Alliance HPLC apparatus (Milford, MA, USA) with photodiode array detector (Waters 2998-PDA). HPLC system was equipped with a column compartment with temperature control, on-line degasser, quaternary pump, auto sampler and auto injector.

Experiments were carried out on a RP C18 (Merk Millipore®) analytical reverse phase column (125 mm×4 mm, 5 μm), maintained at ±25 °C, with isocratic mode. The mobile phase consisted of a mixture of acetonitrile and water with acetic acid (60:40, v/v), and was eluted at a flow rate of 0.8 mL/min. After filtering through a 0.22 μm pore size filter (Millipore, Bedford, USA), 20 μL of the sample was automatically injected and analyzed at 276 nm, and run time was about 3 min. The chromatographic data analysis was performed using Empower Chromatography Software (Milford, MA, USA).

2.3. Preparation of standards and samples

A stock solution of apocynin (1000 μg/mL) was prepared in acetonitrile. From this solution, subsequent dilutions were carried out to obtain eight concentration levels ranging from 5.0 to 100.0 μg/mL. The apocynin samples corresponded to supernatant originated after ultracentrifugation of nanoparticles containing apocynin, as described further. Standard samples were obtained from standard apocynin solution spiked in the blank nanoparticles supernatant. Standards and samples were appropriately diluted in acetonitrile to obtain the desired concentration and filtered through a 0.22 μm pore size filter (Millipore, Bedford, USA) prior to injection.

2.4. System suitability

System suitability (number of theoretical plates (N) and the tailing factor (T)) was evaluated by six replicate analyses of standard apocynin solution (50 μg/mL).

2.5. Method validation

HPLC method was validated according to the parameters described by the International Conference on Harmonization (ICH) guidelines [30]. The following characteristics were considered for validation: linearity, specificity, precision (intra-day and inter-day), accuracy, robustness, limit of detection (LOD) and limit of quantification (LOQ).

2.5.1. Linearity

Linearity was determined through the construction of three independent calibration curves using eight apocynin standards (5, 10, 20, 40, 50, 60, 80 and 100 μg/mL). Linear least squares methodology was applied to calculate the calibration equation and correlation coefficient. The statistical analysis to evaluate the linearity and the deviation from linearity was performed by analysis of variance (ANOVA).

2.5.2. Specificity

Specificity was determined by comparing the representative chromatograms of samples obtained from the supernatant of blank nanoparticles (without apocynin) and samples containing apocynin.

2.5.3. Precision and accuracy

For precision, the intra- and inter-day variations for the determination of apocynin were carried out at three different concentration levels of standard samples (10, 50 and 100 μg/mL) and were expressed in terms of the relative standard deviation (% RSD) and standard deviation (SD). Accuracy was tested by calculating the percent recovery (% recovery) of the mean concentration of apocynin in standard samples at three different concentration levels (10, 50 and 100 μg/mL).

2.5.4. Robustness

Robustness was evaluated by deliberately varying two parameters: (i) flow rate of the mobile phase (0.70 and 0.90 mL/min) and (ii) mobile phase proportion (59:41 and 61:39, v/v), using the standard samples at low (10 μg/mL), medium (50 μg/mL) and high (100 μg/mL) concentration in triplicate. Assessment of change in these parameters was based on the percent recovery and RSD.

2.5.6. Forced degradation of apocynin

Apocynin stock solutions (10, 50 and 100 μg/mL) were used for forced degradation to provide an indication of the stability property and specificity of the proposed method.

For acid- and base-induced degradation, 10 mL of 1 M HCL and 10 mL of 1 M NaOH were added separately into 10 mL of stock solution of apocynin at room temperature and the mixtures were maintained for 1 h before HPLC analysis. For hydrogen peroxide (H2O2)–induced degradation, 10 mL of H2O2 (30%, v/v) was added into 10 mL of stock solution of apocynin and the mixtures were maintained for 1 h before HPLC analysis. For photodegradation product, the drug stock solutions were directly exposed to visible light for 24 h.

2.6. Determination of apocynin encapsulation efficiency in BSA nanoparticles

BSA nanoparticles containing apocynin were obtained by desolvation method as described by Khalil et al. [31]. Mean particle size was determined by laser light scattering.

Apocynin content in nanoparticles was determined indirectly. Supernatant obtained from the ultracentrifugation process of formed nanoparticles was diluted in the mobile phase (1:10, v/v) and filtered through a 0.22 μm pore-size filter, and the drug concentration was obtained by the HPLC method developed and validated. The amount of apocynin encapsulated (encapsulation efficiency) was determined in triplicate, according to Eq. (3).
\[
\text{EE (\%)} = \frac{\text{AI} - \text{AF}}{\text{AI}} \times 100\%
\]

where \(\text{AI}\) is the amount of apocynin initially added to the formulation and \(\text{AF}\) is the amount of the free apocynin quantified in the supernatant after ultracentrifugation.

### 3. Results and discussion

#### 3.1. Chromatography

Initial tests were performed using mixtures of methanol and water, based on the existing methods for the determination of apocynin in plasma [27,13]. Several ratios of these solvents were tested and none of them resulted in a symmetric peak, in our attempts. Posteriorly, acetonitrile and water in various proportions were tested, but a favorable peak was not obtained. The addition of acetic acid in water promoted an improvement in the peak characteristics. Thus, acetonitrile and the acidified water mixture in proportion of 60:40 (v/v) eluted at a flow rate of 0.8 mL/min associated with other parameters such as column temperature (25 °C), sample temperature (25 °C), injection volume (20 µL) and wavelength (276 nm) showed the regular and symmetrical apocynin peak. In these conditions, apocynin was detected in approximately 1.65 min (Fig. 1). The system suitability was analyzed, and \(T\) value was 0.937±0.024 and \(N\) value was 6388±64.32. The parameters analyzed followed the specified limits (\(T < 2; N > 2000\)).

#### 3.2. Method validation

##### 3.2.1. Linearity

Linearity of the HPLC analytical method was evaluated at eight concentration levels (5, 10, 20, 40, 50, 60, 80 and 100 µg/mL) by calculation of regression equation \(y=93,500x + 2340\) and correlation coefficient \((r=0.999)\) using the method of least squares. The correlation coefficient near one indicates linearity in the proposed range. The validity of the test was confirmed by ANOVA, which showed that the regression was significant and the linearity deviation was not significant \((p < 0.01)\).

##### 3.2.2. Specificity

To evaluate specificity, interferences of nanoparticles components were examined in the chromatographic peak of apocynin. Blank nanoparticles (without apocynin) were prepared and the recovered supernatant was diluted in acetonitrile and analyzed by the described HPLC method and the resulting chromatogram (Fig. 2) was compared with that of apocynin sample (Fig. 3) and apocynin standard (Fig. 1). A peak near apocynin retention time was observed in the chromatogram of the blank nanoparticles, but the peak is so small that it does not interfere with quantitative determination of apocynin in nanoparticles. To verify it, a standard sample (supernatant of blank nanoparticles spiked with standard apocynin solution) was analyzed and compared to the apocynin standard solution, at the same concentration. The recovery of apocynin was 99.98%.

##### 3.2.3. Precision and accuracy

Apocynin standard samples (10, 50 and 100 µg/mL) were prepared in triplicate, and analyzed under the same conditions/on the same day (repeatability) and on three different days (intermediate precision). Neither of the precisions exceeded the required RSD value (Table 1). The maximum RSD value was 1.32%.

Accuracy was assessed as the percent recovery at three different concentration levels and is described in Table 1, indicating the accuracy of the method.

##### 3.2.4. Robustness

Robustness was assessed by calculating the percent recovery and RSD of the mean concentration of apocynin standard samples at three different concentrations obtained using different parameters for mobile phase flow rate and ratio of mobile phase (Table 2). The method was

![Fig. 1. Chromatogram of apocynin standard solution (50 µg/mL).](image1)

![Fig. 2. Chromatogram of supernatant from blank nanoparticles.](image2)

![Fig. 3. Chromatogram of supernatant from apocynin nanoparticles (apocynin sample).](image3)

### Table 1

| Nominal concentration (µg/mL) | Precision (% RSD) | Accuracy (% recovery) |
|-----------------------------|-------------------|-----------------------|
|                             | Intra-day         | Inter-day             |                      |
| 10                          | 0.17              | 0.83                  | 104.43               |
| 50                          | 0.23              | 1.32                  | 101.22               |
| 100                         | 0.17              | 1.22                  | 100.37               |
proved to be robust considering changes in mobile phase volume ratio, but sensible with changes in mobile phase flow rate.

3.2.5. LOD and LOQ

LOD and LOQ were calculated from the values obtained from linear regression of a calibration curve, with information on the average standard deviation of the y-intercept (σ) and the slope (b) of the analytical curve, using the Eqs. (1) and (2). The values for LOD and LOQ were 78 ng/mL and 238 ng/mL, respectively.

3.2.6. Stability-indicating property

The chromatograms of the samples treated with acid, base, H$_2$O$_2$ and visible light showed well separated peak of apocynin standard as well as some additional peaks at different retention times of apocynin. The chromatograms of the apocynin samples were compared with the chromatogram of apocynin standard solution. The chromatogram of apocynin standards exposed to visible light for 24 h showed no additional peaks (data not shown), suggesting the stability of apocynin in visible light. However, acid, base and H$_2$O$_2$ induced apocynin degradation, as shown in Figs. 4–6. The chromatogram of the acid degraded the apocynin sample showed one additional peak at retention time of 1.10 min (Fig. 4). The chromatogram of the base degraded sample showed only one peak at 1.25 min (Fig. 5), and apocynin peak was not detected. The chromatogram of the apocynin sample treated with 30% (v/v) H$_2$O$_2$ showed an additional peak at 1.25 min (Fig. 6). Also, percent recovery of apocynin after stress conditions was calculated and listed in Table 3. The exposure of apocynin standards to acid and H$_2$O$_2$ conditions to acid and H$_2$O$_2$ conditions leads to a mild degradation since the percent recovery was close to 96%–97%. When treated with 1 M NaOH, apocynin was not detected at the same retention time and, thereby, it was not possible to calculate percent of recovery, suggesting drug degradation. The percent recovery of apocynin after exposure to visible light did not exceed the variation of 2%, indicating drug stability in this condition.

Table 2

| Nominal concentration (μg/mL) | Robustness (% recovery±% RSD) |
|-----------------------------|-------------------------------|
|                            | Acetonitrile:0.1% Acetic acid (v/v) | Flow rate (mL/min) |
| 59:41                      | 105.4±0.3 113.1±0.1 | 0.7 0.9 |
| 10                         | 99.9±0.3 117.3±0.1 | 105.4±0.3 107.2±0.7 |
| 50                         | 99.1±0.3 99.4±0.4 | 89.4±0.2 |
| 100                        | 99.7±0.3 100.0±0.1 | 108.3±0.8 90.1±0.1 |

Fig. 4. Chromatogram of acid (1 M HCl) treated apocynin: peak 1, degradant (1.10 min); peak 2, apocynin (1.65 min).

Fig. 5. Chromatogram of base (1 M NaOH) treated apocynin: peak 1, degradant (1.25 min).

Fig. 6. Chromatogram of H$_2$O$_2$ (30%, v/v) treated apocynin: peak 1, degradant (1.25 min); peak 2, apocynin (1.65 min).

Table 3

| Exposure conditions | % recovery ±% RSD |
|---------------------|-------------------|
| UV light            | 100.9±0.55        |
| NaOH                | 96.0±1.60         |
| H$_2$O$_2$          | 96.8±1.34         |

* Mean of the three concentrations (10 μg/mL, 50 μg/mL and 100 μg/mL, n=3).

3.3. Method applicability

BSA nanoparticles containing apocynin were obtained by the desolvation method and presented particle size in the range of 110–230 nm. The encapsulation efficiency of apocynin in nanoparticles was determined by the HPLC method validated in this work, using an indirect method based on the quantitation of free drug present in the supernatant of nanoparticles centrifugation. Specificity assay demonstrated no interference of supernatant products in drug quantitation. The encapsulation efficiency was 80%–90%, showing that nanoparticles present high ability to encapsulate the drug.

After preparation of nanoparticles, characterization is required and an indispensable step is the determination of the drug content within the nanoparticles. This parameter must be properly assessed since the drug must be efficiently loaded into the nanoparticles to reach its therapeutic goal. Therefore, a suitable quantification method needs to be adequately validated to ensure a reliable quantification of the analyte [32,33].

In this study, we described for the first time an HPLC method for the quantification of the apocynin in BSA. The obtaining of apocynin-
loaded nanoparticles is not described in the literature nanoparticles and thus, there are no chromatographic methods to determine apocynin in nanoparticles matrix. The method was proved to be simple, efficient, sensitive and fast, which allows analyzing a large number of samples in a short period; being capable of application to the quantification of apocynin in BSA nanoparticles. Also, as the method separated the drug from its degradation products, it can be employed as a stability-indicating method.

4. Conclusion

The developed HPLC method was precise, accurate, specific and stability-indicating for the determination of apocynin. The method was reproducible and selective for the analysis of apocynin as bulk drug and from BSA nanoparticles. The method was found to be suitable for the determination of apocynin encapsulation efficiency in BSA nanoparticles. It could be further extended and applied to in vitro apocynin release assay and study of degradation kinetics.

Acknowledgments

The authors thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/Brazil (CAPES) for the scholarship.

References

[1] F. Engels, B.F. Renirie, B.A. Hart, et al., Effects of apocynin, a drug isolated from the roots of Pierorhiza kurroo, on arachidonic acid metabolism, FEBS Lett. 305 (1992) 254–256.
[2] S. Hougee, A. Hartog, A. Sanders, et al., Oral administration of the NADPH-oxidase inhibitor apocynin partially restores diminished cartilage proteoglycan synthesis and reduces inflammation in mice, Eur. J. Pharmacol. 531 (2006) 264–269.
[3] K.R. Houser, D.K. Johnson, F.T. Ishmael, Anti-inflammatory effects of methoxyphenolic compounds on human airway cells, J. Inflamm. 9 (2012) 1–12.
[4] J.M. Li, N.P. Gall, D.J. Grieve, et al., Activation of NADPH oxidase during progression of cardiac hypertrophy to failure, Hypertension 40 (2002) 477–484.
[5] M.M. El-Sawalhi, L.A. Ahmed, Exploring the protective role of apocynin, a specific NADPH oxidase inhibitor, in cisplatin-induced cardiotoxicity in rats, Chem. Biol. Interact. 207 (2014) 58–66.
[6] D.K. Miller, C.E. Oelrichs, G.Y. Sun, et al., Subchronic apocynin treatment attenuates methamphetamine-induced dopamine release and hyperactivity in rats, Life Sci. 98 (2014) 6–11.
[7] R.F. Klues, P.C. De Marco, R.M. Salasznik, et al., Apocynin derivatives interrupt intracellular signaling resulting in decreased migration in breast cancer cells, J. Biomed. Biotechnol. 2006 (2006) 1–10.
[8] K. Lirdprapanmongkol, J.P. Kramh, T. Suthiphunghen, et al., Vanillin suppresses metastatic potential of human cancer cells through PI3K inhibition and decreases angiogenesis in vivo, J. Agric. Food Chem. 57 (2009) 3055–3063.
[9] S. Suzuki, P. Pitchakarn, S. Sato, et al., Apocynin, an NADPH oxidase inhibitor, suppresses progression of prostate cancer via Rac1 dephosphorylation, Exp. Toxicol. Pathol. 65 (2013) 1035–1041.
[10] H. Kinoshita, T. Matsumura, N. Ishii, et al., Apocynin suppresses the progression of atherosclerosis in apolipoprotein-deficient mice by inactivation of macrophages, Biochem. Biophys. Res. Commun. 431 (2013) 124–130.
[11] X.N. Tang, B. Cairns, N. Cairns, et al., Apocynin improves outcome in experimental stroke with a narrow dose range, Neuroscience 154 (2008) 556–562.
[12] J.D. Lambeth, K.H. Krause, R.A. Clark, NOX enzymes as novel targets for drug development, Semin. Immunopathol. 30 (2008) 339–363.
[13] K. Wang, L. Li, Y. Song, et al., Improvement of pharmacokinetics behavior of apocynin by nitrore derivatization: comparative pharmacokinetics of nitroene-apocynin and its parent apocynin in rats, PLoS One 8 (2013) e70189.
[14] B.J. Connell, M.C. Saleh, B.V. Khan, et al., Apocynin may limit total cell death following cerebral ischemia and reperfusion by enhancing apoptosis, Food Chem. Toxicol. 9 (2011) 43063–43069.
[15] V.A. Moharraj, Y. Chen, Nanoparticles – a review, Trop. J. Pharm. Res. 5 (2006) 561–573.
[16] N.M. Khalil, E. Carraro, L.F. Cótica, et al., Potential of polymeric nanoparticles in AIDS treatment and prevention, Expert Opin. Drug Deliv. 8 (2011) 95–112.
[17] N.M. Khalil, T.C. de Nascimento, D.M. Casa, et al., Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats, Colloids Surf. B 101 (2013) 353–360.
[18] C.D. Rodrigues, D. Meza Casa, L.F. Dalmonil, et al., Amphotericin b-loaded poly(lactide)-poly(ethylene glycol)-blend nanoparticles: characterization and in vitro efficacy and toxicity, Curr. Nanosci. 9 (2013) 594–598.
[19] A. Frank, E. Prigden, L.K. Molnar, et al., Factors affecting the clearance and biodistribution of polymeric nanoparticles, Mol. Pharm. 5 (2008) 505–515.
[20] N.M. Khalil, R.M. Mainardes, Colloidal polymeric nanoparticles and brain drug delivery, Curr. Drug Deliv. 6 (2009) 261–273.
[21] A. Kumari, S.K. Yadav, S.C. Yadav, Biodegradable polymeric nanoparticles based drug delivery systems, Colloids Surf. B 75 (2010) 1–18.
[22] G. Barratt, Colloidal drug carriers: achievements and perspectives, Cell. Mol. Life Sci. 60 (2003) 21–37.
[23] M. Ulbricht, Advanced functional polymer membranes, Polymer 47 (2006) 2217–2262.
[24] Z. Dongmei, Z. Xiuha, Z. Zhang, et al., Preparation, characterization, and in vitro targeted delivery of ficolate-decorated paclitaxel-loaded bovine serum albumin nanoparticles, Int. J. Nanomed. 5 (2010) 669–677.
[25] A.O. Elzoughby, W.M. Samy, N.A. Elgindy, Albumin-based nanoparticles as potential controlled release drug delivery systems, J. Control. Release 157 (2012) 168–182.
[26] M. Rahimnejad, G. Najafpour, G. Bakeri, Investigation and modeling effective parameters influencing the size of BSA protein nanoparticles as colloidal carriers, Colloids Surf. A 412 (2012) 96–100.
[27] Q. Wang, R.E. Smith, R. Luchtefeld, et al., Bioavailability of apocynin through its conversion to licocynogulate but not to diapoxyn, Phytochemistry 15 (2008) 496–503.
[28] K.A. Trumbull, D. McAllister, M.M. Gandelman, et al., Diapoxyn and apocynin administration fails to significantly extend survival in G93A SOD1 ALS mice, Neurobiol. Dis. 45 (2012) 137–144.
[29] H. Chandasa, Y.S. Chhonker, V. Bala, et al., Pharmacokinetic, bioavailability, metabolism and plasma protein binding evaluation of NADPH-oxidase inhibitor apocynin using LC–MS/MS, J. Chromatogr. B 985 (2015) 180–188.
[30] ICH–International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Q2B–Validation of Analytical Procedures: Methodology, 2005.
[31] N.M. Khalil, J. Ascari, D.V. Ronik, et al., Processo de formulação de nanopartículas de apocinina revestidas com o polímero natural BSA e reticuladas com gliceraldeído pelo método de coacervação e fármaco 2014, Patente: Número Do Registro: BR 10 2014 029625-5 A2, 2014. Brasil.
[32] G. da Rocha Lindner, N.M. Khalil, R.M. Mainardes, Resveratrol-loaded polymeric nanoparticles: validation of an HPLC-PDA method to determine the drug entrapment and evaluation of its antioxidant activity, Sci. World J. 2013 (2013) 1–9.
[33] J. das Neves, B. Sarmento, M.M. Amijii, et al., Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dапивирине from polymeric nanoparticles, J. Pharm. Biomed. Anal. 52 (2010) 167–172.